Urocortin 2

Drug Profile

Urocortin 2

Alternative Names: NBI 69734; UCN 2; urocortin II

Latest Information Update: 24 Aug 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Clayton Foundation for Research
  • Developer Neurocrine Biosciences
  • Class Hormones; Peptides; Small molecules
  • Mechanism of Action Corticotropin-releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Acute heart failure; Alzheimer's disease; Heart failure; Obesity

Most Recent Events

  • 17 May 2012 Pharmacodynamics and adverse events data from a phase I/II trial in Acute decompensated heart failure released by Neurocrine Biosciences
  • 31 Mar 2012 Neurocrine Biosciences completes the phase I/II UNICORN trial in Acute decompensated heart failure in New Zealand
  • 28 Oct 2010 Phase-II clinical trials in Congestive heart failure in United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top